Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
The objective of this study was to investigate the effect for treatment or prevention of bovine mastitis of the intramammary infusion of recombinant bovine granulocyte-macrophage colony-stimulating factor (rbGM-CSF) produced in transgenic silkworm as a dry cow therapy. As the treatment or preventive trials, the infected or non-infected quarter were assigned at drying-off to an intramammary infusion of rbGM-CSF (400 μg/quarter) solutions. Each milk sample was collected for bacteriological examination and somatic cell count (SCC) at dry-off and a month after calving. In the treatment trial, total bacterial counts and SCC in milk was lower at 0, 7, 14 and 28 days after calving than at dry-off. In the prevention trial, the new intramammary infection of all cows was not detected after calving. These results suggest that the intramammary infusion of rbGM-CSF at drying off has a high potential as an agent of dry cow therapy.
|